Greenhalgh Ellis Skott 4
4 · TELA Bio, Inc. · Filed Nov 13, 2019
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Greenhalgh Ellis Skott
Chief Science Officer
Transactions
- Conversion
Common Stock
2019-11-13+2,025→ 5,623 total - Conversion
Common Stock
2019-11-13+4,887→ 10,510 total - Conversion
Series A Preferred Stock
2019-11-13−50,000→ 0 total→ Common Stock (2,025 underlying) - Conversion
Series B Preferred Stock
2019-11-13−120,699→ 0 total→ Common Stock (4,887 underlying) - Conversion
Warrant (right to buy)
2019-11-13+1,976→ 1,976 totalExercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (80 underlying) - Conversion
Warrant (right to buy)
2019-11-13−1,976→ 0 totalExercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (1,976 underlying)
Footnotes (5)
- [F1]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]Reflects 5,623 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F3]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.